Boosted by the news of being authorized to copy MSD covid-19 oral drug, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Brightgene Bio-Medical Technology Co.Ltd(688166) and other relevant stocks rose sharply on the 21st, but relevant companies and insiders were cautious.
On January 20, the Geneva pharmaceutical patent pool (MPP) announced that it had signed agreements with 27 generic pharmaceutical enterprises to produce molnupiravir, an oral covid-19 antiviral drug, and supply it to 105 low-income and middle-income countries. Among them, five Chinese enterprises have been authorized, namely Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Brightgene Bio-Medical Technology Co.Ltd(688166) , Langhua pharmaceutical under Weiya biology, Shijiazhuang Longze pharmaceutical and Shanghai Desano pharmaceutical.
Affected by this news, as of the closing on January 21, when the biomedical sector fell by 3.15%, the share prices of relevant companies showed strong performance, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) A shares rose by 5.98% and Hong Kong shares rose by 2.81%; Brightgene Bio-Medical Technology Co.Ltd(688166) opening 20cm limit; Weiya biological Hong Kong shares rose 13.86%. Although Shijiazhuang Longze pharmaceutical did not land in the A-share market, the shares of Jiangsu Aidea Pharmaceutical Co.Ltd(688488) were positive, up 10.79%.
Although the authorized news boosted the secondary market, many shareholders exclaimed, “shareholders can start counting boards”. But related companies have shown caution.
On January 21, Brightgene Bio-Medical Technology Co.Ltd(688166) issued an announcement detailing the signing background and contents of the agreement, and said that whether the cooperative drugs produced by the company under this license can obtain the listing approval of the local drug regulatory authority in the region and the listing time in the region are uncertain, The sales of cooperative drugs after listing in the region is affected by (including but not limited to) covid-19 pneumonia epidemic development, market environment, sales channels, production and / or supply chain capacity and many other factors, which are uncertain.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) said that the imitation right of covid-19 oral medicine is in Longze pharmaceutical, where the company shares, and the company holds 4.76% of the equity of Longze pharmaceutical. However, it is not known whether Longze pharmaceutical produces covid-19 generic drug business.
In the context of the sharp rise of relevant stocks, people in the industry also take a cautious attitude and believe that this authorization is difficult to say that it is a significant positive for the performance. Drugs are mainly sold to low-income and middle-income countries, and the price of the product is expected to be lower than that of the original research products or in other middle and high-income countries. In this case, it can not bring too much profit to the enterprise.
Although the impact on future performance remains to be seen, Zheshang Securities Co.Ltd(601878) pointed out that obtaining MPP authorization is an embodiment of the applicant’s global compliance production capacity. Benefiting from the supporting advantages of China chemical industry and the accelerated expansion of compliance capacity, it is expected that China API and cdmo companies will deepen their influence in the global drug supply chain.
